FDA & Government News

FDA Approves New Option in Obesity

The Allurion Gastric Balloon System is now authorized by the US Food and Drug Administration for short-term weight loss in adults aged 22 to 65 years with obesity and a body mass index of 30 to 40 kg/m2.

Share

  • 1

    FDA approved the Allurion Gastric Balloon System.

  • 2

    Designed for adults 22-65 with obesity.

  • 3

    Administered in a 15-minute office visit.

  • 4

    Remains in stomach for about 4 months.

  • 5

    Can have up to 2 balloons in a 10-month period.

  • 6

    Alternative to surgery and glucagon-like peptide-1s.

  • 7

    Demonstrated safety and efficacy in real-world conditions.

Original Source(s)

FDA Approves New Option in Obesity

The Allurion Gastric Balloon System is now authorized by the US Food and Drug Administration for short-term weight loss in adults aged 22 to 65 years with obesity and a body mass index of 30 to 40 kg/m2.

  • by Kathryn Wighton

  • February 23, 2026

  • 3 min

Related Content

Lifestyle Interventions vs Gestational Diabetes

Investigators report that lifestyle interventions during pregnancy reduce gestational diabetes risk, with effects varying by diagnostic criteria and maternal education level.

Weight Regain Rapidly Follows GLP-1 Cessation

Systematic review finds most lost weight returns within two years of stopping weight management medication

Intermittent Fasting Shows No Edge Over Standard Diets

Cochrane review finds the approach produces similar weight loss and quality-of-life outcomes compared with conventional calorie restriction